18th May 2021 15:54
Syncona Ltd - life sciences investor managed by Syncona Investment Management Ltd - Portfolio firm Freeline Therapeutics Holdings PLC reports first quarter results. Pretax loss stretches annually to USD34.9 million from USD16.6 million and generates no revenue, like prior year. Total operating expenses up 60% to USD33.9 million.
Current stock price: 214.18 pence
Year-to-date change: down 18%
By Eric Cunha; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Syncona